Related Experiment Video
Updated: May 15, 2025

06:50
Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
Published on: January 26, 2024
951
Predicting reverse-bound peptide conformations in MHC Class II with PANDORA.
Daniel T Rademaker1,2,3, Farzaneh M Parizi4, Marieke van Vreeswijk3,4
1Biosystems Data Analysis, University of Amsterdam, Amsterdam, Netherlands.
Frontiers in Immunology
|April 8, 2025
Summary
Discoveries reveal peptides can bind Major Histocompatibility Complex (MHC) class II molecules in reverse, activating T cells. PANDORA software now models these reversed peptides, advancing immunotherapy and vaccine design.
Area of Science:
- Immunology
- Computational Biology
- Structural Biology
Background:
- Recent findings show peptides binding to Major Histocompatibility Complex (MHC) class II molecules can adopt a reverse orientation.
- This reverse binding orientation still allows for effective CD4+ T cell activation, challenging existing models of immune recognition.
Purpose of the Study:
- To introduce an updated version of the PANDORA software capable of modeling peptides bound in a reversed orientation to MHC molecules.
- To address the challenge of limited structural data for reversed peptide-MHC complexes.
Main Methods:
- PANDORA utilizes integrative modeling with algorithmically reversed peptides as templates to predict reversed-bound peptide structures.
- The updated PANDORA feature was validated through two experimental studies.
Main Results:
- The new PANDORA feature achieved an average backbone binding-core L-RMSD of 0.63 Å, demonstrating high accuracy.
- Low RMSD values were maintained even when using templates from different MHC alleles and peptide sequences, indicating robustness.
Conclusions:
- The updated PANDORA software is the first tool able to model reversed-bound peptides in MHC class II molecules.
- This advancement is expected to be a valuable resource for the immunology community, supporting the development of targeted immunotherapies and novel vaccine designs.

